CD19 and breast cancer: Previous studies have suggested that ribitol may regulate apoptosis and antioxidant processes, thereby influencing tumor progression.[45,49] We observed a positive correlation between CD19 expression and ribitol levels, and a negative correlation between ribitol levels and BC risk, indicating that this B cell subset may exert protective effects through the enhancement of ribitol-related antitumor metabolic pathways.